福泰製藥 VRTX 深 滬
等待開盤 09-24 09:30:00 美东时间
516.34
+1.350
+0.26%
華盛通- 最 高525.4296
- 今 開515.60
- 成交量 121.41万股
- 最 低 509.56
- 昨 收 514.99
- 總市值 1308.72亿
- 52周最高 560.25
- 市盈率 靜 33.70
- 換手率 0.48%
- 52周最低 400.735
- 委 比 -45.95%
- 總股本 2.53亿
- 歷史最高 560.25
- 量 比 0.97
- 振 幅 3.08%
- 歷史最低 26.50
- 每 手 1
- 風險率 37.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多QUICK SPARK: Viking Therapeutics Stock Gains 40% in 2 Days
Viking Therapeutics (NASDAQ:VKTX) shares are surging after the company reported positive results for its weight-loss drug candidate — the stock gained over 40% in two days. • Vertex Pharmaceuticals stock is trading near recent highs. What’s next for VRTX stock? Vk2735 Holds Weight Loss with Less Fre...
今天 04:54
Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday reported data from its Phase 2b AMPLIFIED trial evaluating inaxaplin in individuals with APOL1-mediated kidney disease (AMKD). The study tested a daily 45 mg dose alongside optimized standard care across two distinct patient groups with ei...
09-23 01:55
Vertex reports positive mid-stage results of inaxaplin for kidney disease
Vertex Pharmaceuticals (VRTX) said that data from a phase 2b trial found that the experimental drug inaxaplin led to a significant decline in proteinuria in individuals with APOL1-mediated kidney dise...
09-22 23:24
Vertex trades higher after JPM gives bullish rating
Vertex Pharmaceuticals (VRTX) stock rose 1.6% premarket on Friday after J.P. Morgan moved to an Overweight rating for the company. The brokerage also set a December 2027 price target of $560 for the s...
09-11 21:30
Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks
The healthcare sector (XLV) gained 4.91% in August, outperforming the broader S&P 500 (SPY), which advanced 2.68% during the month. Healthcare stocks benefited from strength in biotechnology and medic...
09-05 23:05
Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.61% on an annualized basis producing an average annual return of 14.84%. Currently, Vertex Pharmaceuticals has a market capitalization of $139.66 billion. Buying $100 In VRTX: If an investor had bought $100 ...
09-04 23:00
美股大行评级 | 最高735美元！戴尔科技绩后获11家大行上调目标价；MongoDB绩后分歧大，9家上调；4家下调；派拓网络、GitLab、美敦力获多家大行上调目标价
今日重点评级关注：Tigress Financial：维持Liftoff Mobile"买入"评级，目标价从39美元升至41美元；奥本海默：维持SpaceX"跑赢大市"评级，目标价从250美元升至280美元
09-03 13:50
内部人交易｜福泰制药披露一笔股票减持
美股上市公司福泰制药（VRTX）披露一笔内部人股票交易。文件显示，公司内部人Sachs (Bruce I)（Director）2026-08-27减持公司股票...
09-02 07:01
Vertex Pharmaceuticals names Jonathan Poole to CFO role
Vertex Pharmaceuticals (VRTX) named Jonathan Poole, its current SVP of Finance, as executive vice president and CFO, effective Jan. 1, 2027, succeeding Charles Wagner. Wagner, currently EVP and chief ...
09-01 21:30
